Latest Helus Pharma News & Updates

See the latest news and media coverage for Helus. We track all announcements, press releases, and industry mentions in real time, all in one place.

Helus Pharma (Helus)

Mental health biopharmaceutical company

helus.com

Headquarters: Toronto, Canada
Founded year: 2019
Company type: Public company
Number of employees: 100–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Helus Pharma (Helus)

In short: Helus appointed Michael Halstead as CEO, completed Phase 3 enrollment for its depression treatment HLP003, and reported Q1 2027 results.

Company announcements

August 3 Helus

Helus Pharma appoints Michael Halstead as Chief Executive Officer

Halstead, former President of Intra-Cellular Therapies, led its US$14.6 billion sale to Johnson & Johnson and will guide HLP003 through Phase 3 readout expected Q4 2026.

July 21 Helus

Helus completes enrollment in Phase 3 APPROACH study of HLP003

The study evaluates HLP003 as an adjunctive treatment for major depressive disorder, ahead of schedule.

June 29 Helus

Helus Pharma reports fiscal year 2026 financial results and business highlights

The clinical-stage company highlights Phase 3 enrollment progress and $50 million funding, while reporting a net loss of $148 million for the year.

June 25 Helus

Helus Pharma announces US$50 million underwritten offering

The offering of 10.3 million shares at US$4.85 each, led by Cantor and Barclays, closes on June 25, 2026.

Media coverage

August 14 The Globe and Mail

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization - - Completed USD$50...

August 6 Kalkine

Cybin (Helus Pharma, HELP) Leaps 14% Ahead of Pivotal Depression Trial Data

In mid-July, US regulators finalised ... of large pharmaceutical investment into the space. The CEO appointment on 3 August, arriving just before a highly anticipated...

August 5 The Globe and Mail

A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

August 3 The Globe and Mail

Helus Pharma Appoints Michael Halstead as Chief Executive Officer

Johnson & Johnson Experienced executive with a proven track record of guiding pharmaceutical companies through late-stage clinical development and commercialization Appointed as Helus Pharma prepares...

Never miss news about Helus

Track Helus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Helus competitors & trending companies

Browse news for competitors to Helus and other trending companies.